Journey Medical (DERM) investor relations material

Company overview and strategy

• Focused exclusively on dermatology, building a portfolio through acquisition and licensing of FDA-approved products.

• Portfolio includes eight prescription products targeting rosacea, acne, and hyperhidrosis, with markets exceeding $1 billion each.

• Leadership team has deep dermatology experience, leveraging relationships and expertise from prior roles at Medicis.

• Aggressively seeks late-stage and already-approved products to expand the pipeline and sustain growth.

• Current assets provide a long runway, but ongoing business development remains a priority.

EMROSI launch and performance

• EMROSI, a modified-release minocycline for rosacea, launched just over a year ago and has seen strong uptake.

• Achieved over 100,000 prescriptions in its first year, with 3,700+ healthcare providers now prescribing.

• Demonstrated clinical superiority over the previous gold standard, working in as little as two weeks.

• Generated $15 million in revenue in its first three quarters on the market.

• Faces no significant competition in the oral or topical rosacea space, supporting continued momentum.

Market access and reimbursement

• Currently, about 35% of EMROSI prescriptions are reimbursed, with the remainder supported by a co-pay bridging program.

• Signed agreements with the three largest GPOs, covering 85% of U.S. covered lives, to improve formulary access.

• Expects coverage to rise to 60–75% over time, with gradual increases as more plans open up post-launch.

• Benefits from improved average selling price as coverage expands and reliance on bridging programs decreases.

• Time to realize GPO benefits varies, typically six months to a year or more.